Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 97
Filter
1.
Clin Exp Immunol ; 193(1): 103-112, 2018 07.
Article in English | MEDLINE | ID: mdl-29485697

ABSTRACT

Studies of cerebrospinal fluid (CSF) γδ T cells in children are limited, due especially to the lack of control data. In adults, gamma/delta T cells (TCR-γδ) residing in the intrathecal space are sometimes involved in neuroinflammation. To evaluate the possible role of γδ T cells in paediatric neuroinflammation, we immunophenotyped cerebrospinal fluid (CSF) and blood lymphocytes using flow cytometry in a case-control study of 100 children with non-inflammatory neurological disorders (NIND), 312 with opsoclonus-myoclonus (OMS) and 23 with other inflammatory neurological disorders (OIND). In NIND, the negative correlation between CSF γδ T cell frequency and patient age was striking: median frequency of 27% in infants and 3·3% in teens. Interindividual variations were largest in the youngest. There was no gender effect. In all OMS, after correcting for age, only a small effect of OMS severity remained. Measurement of markers for γδ T cell activation [human leucocyte antigen D-related (HLA-DR)], maturation (CD45RA, CD45RO) or intracellular cytokine staining [interleukin (IL)-4, interferon (IFN)-γ] failed to discriminate OMS and NIND groups. Of seven OMS immunotherapies/combinations, none altered the frequency of total CSF γδ T cells or subsets significantly. In OIND, the CSF γδ T cell frequency was < 10% for single samples of other paraneoplastic disorders [anti-neuronal nuclear antibody (ANNA)-1, PCA-1, teratoma-associated syndrome], cerebellar ataxia (post-infectious, ataxia-telangiectasia), acute disseminated encephalomyelitis, neuroborreliosis and encephalitis. This study provides new insights into CSF γδ T cells in the paediatric population. Although their role in CSF remains elusive, the negative age correlation, resistance to immunotherapy and our age cut-off references for NIND are important findings for the design of future paediatric studies.


Subject(s)
Cerebrospinal Fluid/cytology , Nervous System Diseases/immunology , Opsoclonus-Myoclonus Syndrome/immunology , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Age Factors , Case-Control Studies , Child , Child, Preschool , Female , Flow Cytometry , HLA-DR Antigens/immunology , Humans , Infant , Inflammation/immunology , Inflammation/pathology , Interferon-gamma/immunology , Interleukin-4/immunology , Leukocyte Common Antigens/immunology , Lymphocyte Activation/immunology , Male , Nervous System Diseases/pathology , Opsoclonus-Myoclonus Syndrome/pathology
2.
Clin Exp Immunol ; 190(2): 217-225, 2017 11.
Article in English | MEDLINE | ID: mdl-28710878

ABSTRACT

The purpose of this study was to evaluate the capacity of 6-mercaptopurine (6-MP), a known immunosuppressant, to normalize cerebrospinal fluid (CSF) lymphocyte frequencies in opsoclonus-myoclonus syndrome (OMS) and function as a steroid sparer. CSF and blood lymphocytes were immunophenotyped in 11 children with OMS (without CSF B cell expansion) using a comprehensive panel of cell surface adhesion, activation and maturation markers by flow cytometry, and referenced to 18 paediatric controls. Drug metabolites, lymphocyte counts and liver function tests were used clinically to monitoring therapeutic range and toxicity. In CSF, adjunctive oral 6-MP was associated with a 21% increase in the low percentage of CD4+ T cells in OMS, restoring the CD4/CD8 ratio. The percentage of CD4+ T cells that were interferon (IFN)-γ+ was reduced by 66%, shifting the cytokine balance away from T helper type 1 (Th1) (proinflammatory) predominance. The percentage of natural killer (NK) cells decreased significantly in CSF (-32%) and blood (-67 to -82%). Low blood absolute lymphocyte count was more predictive of improvement in CSF lymphocyte proportions (correlated with % CD4+ T cells) than the 6-thioguanine level (no correlation). 6-MP was difficult to titrate: 50% achieved the target absolute lymphocyte count (< 1·5 K/mm); 20%, the 'therapeutic' 6-thioguanine level; and 40% the non-toxic 6-methylmercaptopurine level. Side effects and transaminase elevation were mild and reversible. Clinical steroid-sparing properties and lowered relapse frequency were demonstrated. 6-MP displayed unique pharmacodynamic properties that may be useful in OMS and other autoimmune disorders. Its steroid sparer capacity is limited to children in whom the therapeutic window can be reached without limiting pharmacokinetic factors or side effects.


Subject(s)
CD4-Positive T-Lymphocytes/drug effects , Cerebrospinal Fluid/cytology , Mercaptopurine/pharmacology , Opsoclonus-Myoclonus Syndrome/cerebrospinal fluid , Administration, Oral , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/immunology , Cerebrospinal Fluid/immunology , Child, Preschool , Female , Humans , Immunophenotyping , Inflammation , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Killer Cells, Natural/immunology , Lymphocyte Count , Male , Mercaptopurine/administration & dosage , Mercaptopurine/analogs & derivatives , Mercaptopurine/blood , Mercaptopurine/pharmacokinetics , Neuroblastoma/immunology , Th1 Cells/immunology , Thioguanine/blood , Transaminases/blood
3.
Clin Exp Immunol ; 172(3): 427-36, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23600831

ABSTRACT

Opsoclonus-myoclonus syndrome (OMS) is a neuroinflammatory disorder associated with remote cancer. To understand more clearly the role of inflammatory mediators, the concentration of CXCR3 ligands CXCL10, CXCL9 and CXCL11 was measured in 245 children with OMS and 81 paediatric controls using enzyme-linked immunosorbent assay (ELISA), and CXCR3 expression on CD4(+) T cells was measured by flow cytometry. Mean cerebrospinal fluid (CSF) CXCL10 was 2·7-fold higher in untreated OMS than controls. Intrathecal production was demonstrated by significantly different CXCL10 CSF : serum ratios. The dichotomized 'high' CSF CXCL10 group had higher CSF leucocyte count (P = 0·0007) and B cell activating factor (BAFF) and CXCL13 concentrations (P < 0·0001). CSF CXCL10 did not correlate with clinical severity or relapse using grouped data, although it did in some patients. Among seven types of immunotherapy, including rituximab or chemotherapy, only adrenocorticotrophic hormone (ACTH) monotherapy showed reduced CSF CXCL10, but prospective longitudinal studies of ACTH combination therapies indicated no reduction in CXCL10 despite clinical improvement (P < 0·0001). CXCL10 concentrations were 11-fold higher in CSF and twofold higher in serum by multiplexed fluorescent bead-based immunoassay than enzyme-linked immunosorbent assay, but the two correlated (r = 0·7 and 0·83). In serum, no group differences for CXCL9 or CXCL11 were found. CXCR3 expression on CD4(+) T cells was fivefold higher in those from CSF than blood, but was not increased in OMS or altered by conventional immunotherapy. These data suggest alternative roles for CXCL10 in OMS. Over-expression of CXCL10 was not reduced by clinical immunotherapies as a whole, indicating the need for better therapeutic approaches.


Subject(s)
Chemokine CXCL10/cerebrospinal fluid , Chemokine CXCL11/blood , Chemokine CXCL9/blood , Opsoclonus-Myoclonus Syndrome/immunology , Receptors, CXCR3/metabolism , Adrenocorticotropic Hormone/administration & dosage , B-Cell Activating Factor/cerebrospinal fluid , CD4-Positive T-Lymphocytes/immunology , Case-Control Studies , Chemokine CXCL10/blood , Chemokine CXCL13/cerebrospinal fluid , Child , Child, Preschool , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoassay , Immunotherapy , Infant , Inflammation Mediators/blood , Inflammation Mediators/cerebrospinal fluid , Male , Opsoclonus-Myoclonus Syndrome/blood , Opsoclonus-Myoclonus Syndrome/cerebrospinal fluid , Opsoclonus-Myoclonus Syndrome/therapy , Receptors, CXCR3/blood , Steroids/administration & dosage
4.
Neuropediatrics ; 39(3): 164-71, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18991196

ABSTRACT

To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.


Subject(s)
Adrenocorticotropic Hormone/therapeutic use , Amino Acids/cerebrospinal fluid , Immunotherapy/methods , Opsoclonus-Myoclonus Syndrome/drug therapy , Adrenocorticotropic Hormone/pharmacology , Alanine/cerebrospinal fluid , Alanine/metabolism , Amino Acids/metabolism , Analysis of Variance , Child , Child, Preschool , Chromatography, Gas/methods , Corticosterone/pharmacology , Corticosterone/therapeutic use , Dose-Response Relationship, Drug , Female , Glutamine/cerebrospinal fluid , Glutamine/metabolism , Humans , Lysine/cerebrospinal fluid , Lysine/metabolism , Male , Mass Spectrometry/methods , Opsoclonus-Myoclonus Syndrome/cerebrospinal fluid , Opsoclonus-Myoclonus Syndrome/metabolism , Ornithine/cerebrospinal fluid , Ornithine/metabolism , Phenylalanine/cerebrospinal fluid , Phenylalanine/metabolism , Severity of Illness Index , Taurine/cerebrospinal fluid , Taurine/metabolism , Tyrosine/cerebrospinal fluid , Tyrosine/metabolism
5.
Neurology ; 62(9): 1526-32, 2004 May 11.
Article in English | MEDLINE | ID: mdl-15136676

ABSTRACT

BACKGROUND: Although many lines of evidence suggest an autoimmune etiology, the pathophysiology of opsoclonus-myoclonus syndrome (OMS) remains poorly understood and no immunologic abnormalities have correlated with neurologic severity. Conventional immunotherapies often do not prevent relapse or permanent sequelae. OBJECTIVE: To test the cellular immune hypothesis of OMS in a cross-sectional study and determine if CSF lymphocyte subset analysis provides biomarkers of disease activity. METHODS: The expression of lymphocyte surface antigens was investigated in CSF and blood of 36 children with OMS and 18 control subjects, using a comprehensive panel of monoclonal antibodies to adhesion and activation proteins in combination with anti-CD3 and anti-CD45 antibodies in four-color fluorescence-activated cell sorting. RESULTS: Although most children with OMS had normal CSF cell counts, they exhibited expansion of CD19+ B-cell (up to 29%) and gammadelta T-cell (up to 26%) subsets and a lower percentage of CD4+ T-cells and CD4/CD8 ratio, which persisted even years after disease onset and conventional treatments. The percentage of activated CSF T-cells was also higher. Abnormalities correlated with neurologic severity, as scored blinded from videotapes using a 12-item motor scale, and disease duration. No significant differences were found between tumor and no-tumor groups. In children with neuroblastoma, tumor resection or cancer chemotherapy did not alter immunologic abnormalities. CONCLUSIONS: CSF B- and T-cell recruitment is linked to neurologic signs in pediatric OMS, which may relate to relapses and disease progression.


Subject(s)
B-Lymphocytes/immunology , Biomarkers/cerebrospinal fluid , Immunophenotyping , Paraneoplastic Syndromes, Nervous System/cerebrospinal fluid , T-Lymphocytes/immunology , Antigens, CD19/immunology , Antigens, Surface/immunology , B-Lymphocytes/cytology , Disease Progression , Humans , Lymphocyte Activation , Lymphocyte Count , Lymphocyte Subsets/cytology , Lymphocyte Subsets/immunology , Paraneoplastic Syndromes, Nervous System/immunology , Recurrence , T-Lymphocytes/cytology
6.
Pediatr Neurol ; 25(5): 385-9, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11744313

ABSTRACT

This study demonstrates that chloral hydrate can be used to control daytime myoclonic exacerbations. It reports on four patients with progressive myoclonus epilepsy--three with Unverricht-Lündborg disease (EPM1) and one with progressive external ophthalmoplegia (PEO)--all of whom were taking more than one antiepileptic drug. Response to the liquid formulation was faster than response to the capsule and was preferred by the patients. The unusual feature was less than expected sedation or development of tolerance even at daily doses above 500 mg administered for years. Because chloral hydrate helped to improve quality of life, it should be made available to patients with progressive myoclonus epilepsy as adjunctive therapy. Recent evidence of interactions with various excitatory and inhibitory amino acid neurotransmitter-operated ion channels as a mechanism of action may provide insight into altered neurotransmission in progressive myoclonus epilepsy.


Subject(s)
Chloral Hydrate/therapeutic use , Epilepsies, Myoclonic/drug therapy , Adolescent , Adult , Anticonvulsants/adverse effects , Anticonvulsants/therapeutic use , Child , Chloral Hydrate/adverse effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Drug Tolerance , Epilepsies, Myoclonic/diagnosis , Female , Humans , Long-Term Care , Male , Ophthalmoplegia, Chronic Progressive External/diagnosis , Ophthalmoplegia, Chronic Progressive External/drug therapy , Treatment Outcome , Unverricht-Lundborg Syndrome/diagnosis , Unverricht-Lundborg Syndrome/drug therapy
7.
Clin Neuropharmacol ; 24(6): 352-7, 2001.
Article in English | MEDLINE | ID: mdl-11801811

ABSTRACT

Piracetam is an effective symptomatic treatment for some types of myoclonus in adults. To survey the efficacy and safety of piracetam in pediatric opsoclonus-myoclonus, we conducted an open, randomized, two-period, dose-ranging, double-blind, crossover, clinical trial of five children comparing the antimyoclonic properties of oral piracetam to placebo. We devised and validated a new rating scale, specifically for pediatric opsoclonus-myoclonus. Two parents while blinded were able to identify the active phase by improvement in behavior, but another thought the behavior was worse. None of the patients showed improvement in myoclonus. The adult-equivalent dose of piracetam used in this study, which is threefold higher than that used in previous pediatric studies, was well tolerated and safe. We found our rating scale to be a reliable and useful tool for future studies of opsoclonus-myoclonus in children.


Subject(s)
Myoclonus/drug therapy , Neuroprotective Agents/therapeutic use , Ocular Motility Disorders/drug therapy , Piracetam/therapeutic use , Ataxia/diagnosis , Blood Cell Count , Brain Neoplasms/complications , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Humans , Male , Myoclonus/diagnosis , Myoclonus/etiology , Neuroblastoma/complications , Neuroprotective Agents/adverse effects , Ocular Motility Disorders/diagnosis , Ocular Motility Disorders/etiology , Piracetam/adverse effects , Tremor/diagnosis , Videotape Recording
8.
Semin Pediatr Neurol ; 7(2): 118-30, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10914413

ABSTRACT

With neuroimmunology playing an ever greater role in child neurology, paraneoplastic syndromes--uncommon but often devastating complications of cancer--are in the forefront. Abnormalities of both humoral and cellular immunity support the immunological theory of causation. Through co-complicity of host and tumor factors, targets of immunologically mediated injury remote from the tumor may be damaged or destroyed, giving rise to discrete neurological deficits. In the nervous system, the main targets are neuronal nuclei or cell bodies, structural constituents, surface receptors, synapses, and ion channels. The clinical syndromes and response to treatment differ substantially between children and adults. Current pharmacological and biological therapies, which are nonselective, include noncytotoxic and cytotoxic drugs, intravenous immunoglobulins, plasma exchange, and immunoadsorption, some chosen for induction and others for maintenance. Tumor resection and thymectomy are surgical treatments. Combination immunotherapies allow steroid sparing, targeting of more than one immunologic effector pathway, and deploy an advantageous mixture of early- and late-acting drugs. More selective and efficacious immunotherapies are needed.


Subject(s)
Paraneoplastic Syndromes, Nervous System/diagnosis , Adult , Autoantibodies/immunology , Diagnosis, Differential , Humans , Paraneoplastic Syndromes, Nervous System/immunology , Paraneoplastic Syndromes, Nervous System/therapy
9.
Drugs Today (Barc) ; 35(6): 435-48, 1999 Jun.
Article in English | MEDLINE | ID: mdl-12973390

ABSTRACT

The theoretical goal of the ideal drug - to localize specifically and directly to its intended target, have a high therapeutic index and achieve therapeutic efficacy without side effects - is becoming feasible through improved drug delivery and targeting. The clinical advantages of improved drug delivery include continuously therapeutic drug levels, decreased drug dose, improved patient compliance, increased viability of short-lived pharmaceuticals like peptides and proteins, less invasive routes of administration, reduced drug side effects and simplified dosing. Innovative techniques include antibody-mediated drug release, feedback-responsive delivery systems, manipulation of carrier-mediated transport, microspheres composed of polymers and liposomes, permeabilizers, selective delivery to localized sites and vectors to penetrate the blood-brain barrier. Several delivery systems have been approved and more are in clinical trials. Drug delivery system research has greatly influenced the management of brain tumors, central nervous system infections, chronic pain, drug addiction, epileptic disorders, migraine headaches, neurodegenerative diseases, schizophrenia, spasticity and stroke. For many disorders, optimization of drug delivery will continue to be the therapeutic focus for a long while.

10.
Mov Disord ; 13(3): 522-8, 1998 May.
Article in English | MEDLINE | ID: mdl-9613746

ABSTRACT

Children with the opsoclonus-myoclonus syndrome (OMS) usually respond to corticotropin (adrenocorticotrophic hormone, ACTH) treatment but the mechanism of benefit is unknown. We previously showed that both cerebrospinal fluid (CSF) homovanillic acid (HVA) and 5-hydroxyindole-acetic acid (5-HIAA) concentrations are low in pediatric OMS. In this study, we measured levels of CSF Dopa, catecholamines, deaminated metabolites of catecholamines, as well as HVA and 5-HIAA in eight patients before and during treatment with ACTH. All the children were ACTH-responsive with 50-70% improvement in multiple clinical features of OMS. ACTH treatment reduced the HVA concentration in every child by a mean of 21% (p < 0.001). Treatment with ACTH was associated with significant correlations between dopaminergic markers such as HVA, dihydroxyphenylacetic acid (DOPAC), and Dopa. There were no significant changes in the CSF concentrations of the noradrenergic markers norepinephrine (NE) and dihydroxyphenylglycol (DHPG), or the serotonergic marker 5-HIAA. The only child with a marked inflammatory pattern in CSF, which was reversed by ACTH, was atypical for a large increase in NE and decrease in 5-HIAA during ACTH treatment. Beneficial effects of ACTH in OMS are not associated with normalization of HVA or 5-HIAA levels. The pattern of decreased HVA and unchanged DOPAC levels could reflect decreased extraneuronal uptake of catecholamines (which steroids inhibit) or decreased 0-methylation of catecholamines in nonneuronal cells.


Subject(s)
Adrenocorticotropic Hormone/administration & dosage , Myoclonus/drug therapy , Neurotransmitter Agents/cerebrospinal fluid , Ocular Motility Disorders/drug therapy , 3,4-Dihydroxyphenylacetic Acid/cerebrospinal fluid , Catecholamines/cerebrospinal fluid , Child, Preschool , Dihydroxyphenylalanine/cerebrospinal fluid , Female , Homovanillic Acid/cerebrospinal fluid , Humans , Hydroxyindoleacetic Acid/cerebrospinal fluid , Infant , Male , Myoclonus/cerebrospinal fluid , Ocular Motility Disorders/cerebrospinal fluid , Reference Values
11.
Eur J Paediatr Neurol ; 2(1): 33-9, 1998.
Article in English | MEDLINE | ID: mdl-10726844

ABSTRACT

We measured free choline in cerebrospinal fluid (CSF) of 78 patients with movement disorders of paediatric onset and various controls as a putative index of central phospholipid metabolism. Most of the disorders studied were myoclonic disorders, such as progressive myoclonus epilepsy, the opsoclonus-myoclonus syndrome, and essential myoclonus, but other movement disorders, interictal seizure disorders, and different neurological and nonneurological disorders were also included. There were no significant differences in CSF choline concentrations in myoclonic disorders or other movement disorders compared with controls. The CSF choline levels were lowest in children with seizure disorders including progressive myoclonus epilepsy. In progressive myoclonus epilepsy, the CSF choline values resembled other epileptic disorders rather than other myoclonic disorders. When all the data were analysed collectively, no significant relation of CSF choline was found to patient age, gender, aliquot of CSF measured, or the length of time the sample was stored at -70 degrees C. Separate analyses of data from children and adults showed a trend toward a biphasic relation between patient age and CSF choline which could be pursued in developmental studies of normal subjects. Reduced CSF choline may indicate increased choline incorporation into brain phospholipids, disturbances of choline metabolism, decreased choline release, or non-neural factors.


Subject(s)
Choline/cerebrospinal fluid , Movement Disorders/cerebrospinal fluid , Acetylcholine/cerebrospinal fluid , Adrenocorticotropic Hormone/therapeutic use , Adult , Child , Child, Preschool , Chromatography, High Pressure Liquid/methods , Disease Progression , Epilepsies, Myoclonic/cerebrospinal fluid , Epilepsies, Myoclonic/complications , Female , Humans , Male , Movement Disorders/complications , Movement Disorders/drug therapy , Phospholipids/metabolism
12.
Drugs Today (Barc) ; 34(7): 625-39, 1998 Jul.
Article in English | MEDLINE | ID: mdl-14988762

ABSTRACT

Peripheral neurological paraneoplastic syndromes include some of the most convincingly demonstrated autoimmune disorders. Though rare, they are an important cause of neurological morbidity and mortality, often signaling the presence of an occult tumor. Covered under this heading are disorders of peripheral nerves and nerve roots (neuropathies and radiculopathies), the neuromuscular junction (myasthenic syndromes) and muscle (myopathic syndromes). Electrophysiological studies, laboratory screening for circulating autoantibodies, cerebrospinal fluid analysis and muscle or sensory nerve biopsies in selected cases aid the clinician in making the neurological diagnosis. Discrete components of the nervous system such as the neuromuscular junction's calcium channels (Lambert-Eaton myasthenic syndrome) or acetylcholine receptors (myasthenia gravis) are the targets of immunoaggression. Treatment directed at the tumor and the demonstrable or presumed immunological pathophysiology, assisted by supportive medical care and symptomatic drug therapies, offers the best chance for clinical improvement.

13.
Drugs Today (Barc) ; 34(5): 415-30, 1998 May.
Article in English | MEDLINE | ID: mdl-15010705

ABSTRACT

Neurological paraneoplastic syndromes, sometimes called remote effects of cancer on the nervous system, are rare but important and often devastating complications of cancer. The immunological theory of causation is supported by many different lines of evidence and reasoning which implicate abnormalities of both humoral and cellular immunity. The targets of immunologically mediated injury, although remote from the tumor, may be hard hit and irreversibly damaged, giving rise to discrete syndromes of motor or cognitive impairment. In the CNS, they are neuronal nuclei, cerebellar Purkinjie cells and cell surface glutamate receptors. Although central paraneoplastic neurological syndromes may occur in children or adults, the clinical syndromes and response to treatment differ substantially between the two groups. The current therapeutic armamentarium provides a broad spectrum of nonselective immunotherapies including noncytotoxic and cytotoxic drugs, intravenous immunoglobulins and plasma exchange, some selected for induction and others for maintenance. Combination immunotherapies allow steroid sparing and targeting of more than one immunologic effector pathway, and deploy an advantageous mixture of early- and late-acting drugs. More selective and efficacious immunotherapies are needed.

14.
Drugs Today (Barc) ; 34(6): 507-23, 1998 Jun.
Article in English | MEDLINE | ID: mdl-15010712

ABSTRACT

New information about paraneoplastic neurological syndromes, or the remote effects of cancer, has raised more questions than answers. The underlying mechanisms of brain injury remain to be elucidated. A brief review of autoimmunity provides a basis for exploring hypotheses of induction of the immune system by a tumor in the periphery and its subsequent attack on the brain. Onconeural antigens shared by tumors and the brain are the targets of immunologically mediated injury. What provokes the immune system to inappropriately autoaggress and cause autoimmune disease is unknown, but the mechanisms of molecular mimicry or superantigens provide plausible explanations. The root of the problem appears to be a failure of immunoregulation on some level. The more precisely the immunological defect can be defined, the more select the possible therapy. Selective immunotherapies, now available or in preclinical and clinical trials, have great therapeutic potential but require precise information on the underlying immunological problem. These data will provide new directions for immunologic research and therapy in CNS paraneoplastic syndromes.

15.
J Pediatr ; 130(6): 878-84, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9202608

ABSTRACT

OBJECTIVE: Opsoclonus-myoclonus (OM) is a rare neurologic syndrome affecting children and adults. In children it occurs as a parainfectious process or a paraneoplastic syndrome in association with neuroblastoma. Evidence for an immune mechanism includes the presence of serum autoantibodies to several neural antigens and improvement of symptoms with immunosuppressive therapy. We studied the neural antigenic targets of serum IgM and IgG autoantibodies from nine children with OM. DESIGN: We studied sera from nine children with OM, three with associated neuroblastoma and six with a prodromal viral illness. Control subjects (n = 77) included four children with neuroblastoma but not OM, 32 children with other neurologic disorders, and 41 with nonneurologic illnesses. We studied the neural antigenic targets of serum IgM and IgG autoantibodies by the following methods: (1) immunostaining of human cerebellar sections and peripheral nerve, and (2) Western blot analysis with human brain fractions including white matter, gray matter, and cerebellar Purkinje cells and nuclei. RESULTS: Sera from all nine children with OM had IgM and IgG binding to the cytoplasm of cerebellar Purkinje cells and to some axons in white matter. In peripheral nerve, IgM and IgG from all nine OM sera bound to large and small axons. Western blot analysis showed a distinctive pattern of binding to several neural proteins, including a 210 kd antigen identified as the high molecular weight subunit of neurofilament. No control serum showed a similar pattern of reactivity. CONCLUSION: Opsoclonus-myoclonus syndrome in childhood is associated with a distinctive pattern of serum IgM and IgG binding to neural tissues and antigens.


Subject(s)
Antigens/analysis , Autoantibodies/blood , Brain/metabolism , Myoclonus/immunology , Ocular Motility Disorders/immunology , Adolescent , Binding Sites , Blotting, Western , Cerebellum/metabolism , Child, Preschool , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/metabolism , Immunoglobulin M/blood , Immunoglobulin M/metabolism , Infant , Infant, Newborn , Male , Myoclonus/etiology , Neuroblastoma/complications , Ocular Motility Disorders/etiology , Paraneoplastic Syndromes/complications , Purkinje Cells/metabolism , Syndrome
16.
Nat Genet ; 15(3): 298-302, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9054946

ABSTRACT

Progressive myoclonus epilepsy type 1 (EPM1, also known as Unverricht-Lundborg disease) is an autosomal recessive disorder characterized by progressively worsening myoclonic jerks, frequent generalized tonic-clonic seizures, and a slowly progressive decline in cognition. Recently, two mutations in the cystatin B gene (also known as stefin B, STFB) mapping to 21q22.3 have been implicated in the EPM1 phenotype: a G-->C substitution in the last nucleotide of intron 1 that was predicted to cause a splicing defect in one family, and a C-->T substitution that would change an Arg codon (CGA) to a stop codon (TGA) at amino acid position 68, resulting in a truncated cystatin B protein in two other families. A fourth family showed undetectable amounts of STFB mRNA by northern blot analysis in an affected individual. We present haplotype and mutational analyses of our collection of 20 unrelated EPM1 patients and families from different ethnic groups. We identify four different mutations, the most common of which consists of an unstable approximately 600-900 bp insertion which is resistant to PCR amplification. This insertion maps to a 12-bp polymorphic tandem repeat located in the 5' flanking region of the STFB gene, in the region of the promoter. The size of the insertion varies between different EPM1 chromosomes sharing a common haplotype and a common origin, suggesting some level of meiotic instability over the course of many generations. This dynamic mutation, which appears distinct from conventional trinucleotide repeat expansions, may arise via a novel mechanism related to the instability of tandemly repeated sequences.


Subject(s)
Cystatins/genetics , DNA Transposable Elements , Epilepsies, Myoclonic/genetics , Mutation , Base Sequence , Chromosomes, Human, Pair 21 , Cystatin B , Cysteine Proteinase Inhibitors/genetics , DNA Primers , Female , Haplotypes , Humans , Male , Molecular Sequence Data , Pedigree , Polymerase Chain Reaction , Polymorphism, Genetic , Regulatory Sequences, Nucleic Acid , Repetitive Sequences, Nucleic Acid
17.
Clin Neuropharmacol ; 19(6): 507-14, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8937789

ABSTRACT

The immediate serotonin (5-HT) precursor, 5-hydroxy-L-tryptophan (L-5-HTP), is an investigational treatment for myoclonic disorders. Its mechanism of action in humans is incompletely understood. We measured the density of subtypes of 5-HT1 and 5-HT2 receptors and the affinity of 5-HT and L-5-HTP in vitro in the human brainstem and cortex, regions associated with subcortical and cortical myoclonus, respectively. In the cortex, the rank order of 5-HT receptor subtype Bmax was 5-HT2A (low-affinity), 5-HT1A, 5-HT uptake sites, 5-HT1D, 5-HT2C, 5-HT1E/F, and 5-HT2A (high-affinity) sites. In the brainstem, the rank order was 5-HT uptake sites, 5-HT1D, 5-HT2C, 5-HT1A, and 5-HT2A(L) sites. Specific binding at 5-HT1E/F and high-affinity 5-HT2A sites was too low for characterization. In competition studies, 5-HT had high affinity for 5-HT1A and 5-HT2C sites in the brainstem and cortex, but L-5-HTP was > 1,000-fold less active. These data support the hypothesis that in humans L-5-HTP stimulates 5-HT receptors in the CNS only after conversion to 5-HT. They also indicate in the human brainstem a prominence of 5-HT1A sites and paucity of 5-HT1D, 5-HT1E/F, and 5-HT2A sites, which has implications for brainstem-mediated myoclonus and response to serotonergic drugs.


Subject(s)
Brain Stem/ultrastructure , Myoclonus/metabolism , Receptors, Serotonin/classification , Receptors, Serotonin/metabolism , 5-Hydroxytryptophan/metabolism , Adult , Aged , Binding, Competitive , Brain Stem/metabolism , Cerebral Cortex/metabolism , Cerebral Cortex/ultrastructure , Female , Humans , Kinetics , Male , Middle Aged , Serotonin/metabolism
19.
J Child Neurol ; 11 Suppl 1: S13-22, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8959457

ABSTRACT

Movement disorders are a well-recognized feature of some patients with cerebral palsy and often require treatment. However, treatments have been symptomatic and empiric, and there have been few pharmacologic studies. The major movement disorders in cerebral palsy are dystonia and the hyperkinesias choreoathetosis and myoclonus. They may occur in combination, often accompanied by spasticity and sometimes by epilepsy. Some drugs are useful treatments for all of these problems, but others may improve one while worsening another. Pitfalls in management include not diagnosing metabolic/degenerative disorders, which may mimic cerebral palsy, or not recognizing reversible complications of cerebral palsy, which may exacerbate symptoms. This review attempts to summarize empiric drug use and recommendations for therapy, drug studies in extrapyramidal cerebral palsy, and prospects for new drugs or models for the problem. Many new pharmacologic agents are available for study in cerebral palsy. Better methods of detecting basal ganglia injury after perinatal injury in asymptomatic infants may allow early intervention in the biologic process of recovery and adaptation.


Subject(s)
Cerebral Palsy/complications , Movement Disorders/drug therapy , Administration, Oral , Anti-Anxiety Agents/therapeutic use , Anticonvulsants/therapeutic use , Dopamine Agents/therapeutic use , Humans
20.
J Child Neurol ; 11(5): 355-69, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8877602

ABSTRACT

The pharmacologic armamentarium used to treat dyskinesias in childhood is increasing. Anticonvulsant drugs as a class are still some of the broadest-spectrum antidyskinetic agents, probably because the class includes so many differently acting drugs or because dyskinesias are manifestations of subcortical electrical events. This group is enhanced by recent developments in gamma-aminobutyric acid and glutamate receptor pharmacology, which promise new antidyskinetic drugs. Other drugs acting at receptors for monoamines (dopamine, norepinephrine, and serotonin), acetylcholine, opioids, or histamine may provide symptomatic improvement. Fewer pharmacotherapies address the underlying pathophysiology of movement disorders. Of these, drugs or biologicals for immunomodulation are the most developed, but the group also includes antioxidants, cofactors, metabolic inhibitors, and chelators. There is potential for drugs that block the neurotoxic effects of glutamate to treat movement disorders and reverse or prevent brain injury. Peripheral blockade of focal dyskinesias through botulinum toxin offers a useful alternative to drugs in some patients.


Subject(s)
Movement Disorders/drug therapy , Child , Drug Therapy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...